Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I–III HER2‐Positive Breast Cancer: A Phase II Clinical Trial

LESSONS LEARNED: This is the first trial to explore the neoadjuvant therapy of pyrotinib in HER2‐positive operable and locally advanced breast cancer, in combination with epirubicin plus cyclophosphamide followed by docetaxel plus trastuzumab. Results primarily showed that pyrotinib in combination w...

Descripción completa

Detalles Bibliográficos
Autores principales: Xuhong, Juncheng, Qi, Xiaowei, Tang, Peng, Fan, Linjun, Chen, Li, Zhang, Fan, Tan, Xuanni, Yan, Wenting, Zhong, Ling, He, Cheng, Liang, Yan, Ren, Lin, Wang, Minghao, Zhang, Yi, Jiang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108050/
https://www.ncbi.nlm.nih.gov/pubmed/33000490
http://dx.doi.org/10.1002/onco.13546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108050/
https://www.ncbi.nlm.nih.gov/pubmed/33000490
http://dx.doi.org/10.1002/onco.13546

Ejemplares similares